Zentalis Pharmaceuticals, Inc. (ZNTL)
| Previous Close | 10.43 |
| Open | 10.54 |
| Bid | 10.24 x 900 |
| Ask | 10.28 x 800 |
| Day's Range | 10.05 - 10.48 |
| 52 Week Range | 9.56 - 31.46 |
| Volume | |
| Avg. Volume | 1,051,204 |
| Market Cap | 725.349M |
| Beta (5Y Monthly) | 1.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.56 |
| Earnings Date | Feb 28, 2024 - Mar 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.90 |
Simply Wall St.David Johnson Bought 16% More Shares In Zentalis Pharmaceuticals
Investors who take an interest in Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) should definitely note that the...
GlobeNewswireZentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen
Investor call to be held on Friday, November 10th, at 10:00 a.m. ET Company also to participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15th, 2023 at 8:30 a.m. GMT NEW YORK and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, toda
- GlobeNewswire
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on track for first NDA submission in a gynecologic malignancy in 2026 Sharing key clinical milestones through 2026 for azenosertib and ZN-d5 $517 million cash balance as of September 30, 2023, with projected cash runway into 2026 Chief Translational Officer, Mark Lackner, Ph.D., to succeed Co-Founder, K
